Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes i

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaborati

BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASD

SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN),

AstraZeneca (LON: AZN - Get Free Report)'s stock had its "buy" rating reiterated by research analyst

Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical

In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the p

Citi raised its target price for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical

AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-ge

Park National Corp OH purchased a new position in Astrazeneca Plc (NYSE: AZN) during the third quart

$1 billion investment will grow AstraZeneca’s workforce in Massachusetts by over 50% and deliver nex

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the opening of its newest global stra

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast an

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closi

Astrazeneca (NYSE: AZN - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both

AstraZeneca (AZN), the oncology and biopharmaceutical company, expanded its cancer-drug collaboratio

AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab com

AstraZeneca and Daiichi Sankyo have entered into ​a clinical collaboration with ‌Summit Therapeutics

Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Typ

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial col

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered

Seven hundred thousand seniors have already started GLP-1s through Medicare, and AstraZeneca just pu

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to

On September 29, 2026, AstraZeneca PLC (AZN) shares fell 1.2%, bringing the current price to $164.21

AstraZeneca buys $2 billion in Summit Therapeutics equity to test ivonescimab with ADCs, providing c

AstraZeneca invests $2 billion in Summit Therapeutics to combine cancer drugs ivonescimab and Sone-V

Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors

https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment

Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically m

https://www.astrazeneca.com/media-centre/press-releases/2026/perioperative-imfinzi-plus-neoadjuvant-

The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer,

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radio

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

On Monday, AstraZeneca (NASDAQ:AZN) discussed second-quarter financial results during its earnings c

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead

CNBC traders picked AstraZeneca, Leidos, 10-year Treasuries and Expeditors; strong earnings lifted L

Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipe

AstraZeneca announced long-term survival data for Tagrisso and Enhertu in lung cancer, alongside bre

Longest survival data ever reported in a global Phase III trial in this settingNew data reinforce TA

6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapyAstraZene

Cramer avoids AstraZeneca, Joby and Grab; favors Trinity, Nucor over Reliance, and praises Simon Pro

AstraZeneca secured FDA approval for its breast cancer drug Etcamah and reported positive Phase 3 tr

https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-

AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhe

AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophil

Statistically significant and clinically meaningful disease and symptom improvements compared to pla

Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Pla

The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (dat